In vitro interactions of licensed and novel antifungal drugs against Fusarium spp

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 1, 2004, Pages 69-71

  Ortoneda, Montserrat ^a   Capilla, Javier ^a   Pastor, F Javier ^a   Pujol, Isabel ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; NAPHTHALENE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE; QUINAZOLINE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; FUSARIUM; FUSARIUM OXYSPORUM; HUMAN; IN VITRO STUDY; LICENSING; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PAECILOMYCES; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 0842346202     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.09.003     Document Type: Article

References (18)

1. Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 46:2002;245-247.
2. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., Walsh T.J. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 46:2002;828-833.
3. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy ten years'experience at a cancer center and implications for management . Blood. 90:1997;999-1008.
4. Capilla J., Ortoneda M., Pastor F.J., Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother. 45:2001;2635-2637.
5. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., Walsh T.J. Synergy, pharmacodinamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin K and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother. 45:2001;3310-3321.
6. Ernst E.J. Investigational antifungal agents. Pharmacother. 21:(Pt 2):2001;165S-174S.
7. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 39:2001;954-958.
8. Guarro J., Gené J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis. 14:1995;741-754.
9. Meletiadis J., Mouton J.W., Meis J.F.G.M., Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 47:2003;106-117.
10. National Committee for Clinical Laboratory Standards. (2002). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Ortoneda M., Capilla J., Pastor F.J., Pujol I., Guarro J. Efficacy of liposomal amphothericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother. 46:2002;2273-2275.
12. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 46:2002;3039-3041.
13. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi report from SENTRY Antimicrobial Surveillance Program, 2000 . Antimicrob Agents Chemother. 46:2002;1032-1037.
14. Polak A. The past, present and future of antimycotic combination therapy. Mycoses. 42:1999;355-370.
15. Pontón J., Rüchel R., Clemons K.V., Coleman D.C., Grillot R., Guarro J., Aldebert D., Ambroise-Thomas P., Cano J., Carrillo-Muñoz A.J., Gené J., Pinel C., Stevens D.A., Sullivan D.J. Emerging pathogens. Med Mycol. 38:(Suppl 1):2000;225-236.
16. Pujol I., Guarro J., Gené J., Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother. 39:1997;163-167.
17. Ryder N.S., Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol. 39:2001;91-95.
18. Sugar A.M. Overview antifungal combination therapy . Curr Opinion Invest Drugs. 2:2001;1364-1365.